Mark Ainsworth
- Advanced Numerical Methods in Computational Mathematics
- Inflammatory Bowel Disease
- Numerical methods in engineering
- Microscopic Colitis
- Electromagnetic Simulation and Numerical Methods
- Advanced Mathematical Modeling in Engineering
- Immunodeficiency and Autoimmune Disorders
- Lattice Boltzmann Simulation Studies
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Electromagnetic Scattering and Analysis
- Advanced Numerical Analysis Techniques
- Model Reduction and Neural Networks
- SARS-CoV-2 and COVID-19 Research
- Differential Equations and Numerical Methods
- Biosimilars and Bioanalytical Methods
- Computational Fluid Dynamics and Aerodynamics
- SARS-CoV-2 detection and testing
- Innovations in Medical Education
- Liver Disease Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Esophagitis
- Pharmaceutical studies and practices
- Distributed and Parallel Computing Systems
- Intensive Care Unit Cognitive Disorders
Odense University Hospital
1997-2025
John Brown University
2015-2024
Oxford University Hospitals NHS Trust
2015-2024
University of Oxford
2017-2024
University of Southern Denmark
2000-2024
Brown University
2015-2024
Imperial College London
2022-2024
University of Liverpool
2022-2023
Newcastle upon Tyne Hospitals NHS Foundation Trust
2023
Manchester Academic Health Science Centre
2023
The impact of COVID-19 on physical and mental health employment after hospitalisation with acute disease is not well understood. aim this study was to determine the effects COVID-19-related employment, identify factors associated recovery, describe recovery phenotypes. Post-hospitalisation (PHOSP-COVID) a multicentre, long-term follow-up adults (aged ≥18 years) discharged from hospital in UK clinical diagnosis COVID-19, involving an assessment between 2 7 months discharge, including detailed...
Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated cost-effectiveness interventions defined by an algorithm designed identify specific therapeutic failure.Randomised, controlled, single-blind, multicentre study. 69 patients with IFX failure were randomised (5 mg/kg every 4 weeks) (n=36) or based on serum and antibody levels using proposed (n=33). Predefined...
<h2>Summary</h2><h3>Background</h3> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. Serology considered key to population-level surveillance potentially individual-level risk assessment. However, immunoassay performance not been compared on large, identical sample sets. We aimed investigate the of four high-throughput commercial SARS-CoV-2 antibody immunoassays novel...
No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge COVID-19, identify factors associated patient-perceived recovery, and potential therapeutic targets by describing the underlying inflammatory profiles of previously described clusters at 5 months discharge.
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying severity in an integrated comparison influenza sepsis versus healthy volunteers. identify signatures correlates host response. Hallmarks disease involved cells, their inflammatory mediators networks, including progenitor cells myeloid lymphocyte subsets, features the repertoire,...
<ns3:p><ns3:bold>Background:</ns3:bold> The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out evaluate the performance ELISA lateral flow immunoassay (LFIA) devices.</ns3:p><ns3:p> <ns3:bold>Methods:</ns3:bold> tested plasma COVID (severe acute respiratory...
ABSTRACT Background The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out evaluate the performance ELISA lateral flow immunoassay (LFIA) devices. Methods tested plasma COVID (SARS-CoV-2) IgM IgG antibodies by using nine different LFIA used a panel samples who...
One in ten severe acute respiratory syndrome coronavirus 2 infections result prolonged symptoms termed long disease (COVID), yet phenotypes and mechanisms are poorly understood
The dispersive properties of high order finite element schemes are analyzed in the setting Helmholtz equation, and an explicit form discrete dispersion relation is obtained for elements arbitrary order. It shown that numerical displays three different types behavior, depending on size method relative to mesh-size wave number. Quantitative estimates behavior rates decay error differing regimes. All fully be sharp. Limits obtained, where transitions between regimes occur, used provide...
Introduction. Reasons for infliximab failure in Crohn's disease and ulcerative colitis are debated. Serum levels of anti-infliximab antibodies have been associated with loss response. We aimed at determining cut-off antibody concentrations clinical response to maintenance therapy. Methods. Patients inflammatory bowel (n = 106) were retrospectively classified as having maintained or Trough measured by fluid-phase radioimmunoassays. Results. Infliximab significantly lower, higher, patients...
Abstract An a‐posteriori error estimator for finite element analysis proposed by Zienkiewicz and Zhu is analysed shown to be effective convergent. In addition we analyse wider classes of estimators which the Zienkiewicz–Zhu a special case. It that some these will asymptotically exact . Numerical evidence presented supporting analysis.
We derive a fractional Cahn--Hilliard equation (FCHE) by considering gradient flow in the negative order Sobolev space $H^{-\alpha}$, $\alpha\in [0,1]$, where choice $\alpha=1$ corresponds to classical while $\alpha=0$ recovers Allen--Cahn equation. The existence of unique solution is established and it shown that preserves mass for all positive values $\alpha$ indeed reduces free energy. then turn delicate question $L_\infty$ boundedness establish an bound FCHE case nonlinearity quartic...
To investigate if the combined assessment of anti-infliximab antibodies (Ab) and degree TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict response to treatment in patients with Crohn's disease (CD).Three groups CD patients, total 33 treated were retrospectively selected: (a) a maintained throughout treatment; (b) good initial response, but subsequent loss response; (c) inadequate first two or three doses. Blood samples analyzed for TNF-alpha-BC Ab using fluid-phase...
The Cancer Genomics Hub (CGHub) is the online repository of sequencing programs National Institute (NCI), including Atlas (TCGA), Cell Line Encyclopedia (CCLE) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) projects, with data from 25 different types cancer. CGHub currently contains >1.4 PB data, has grown at an average rate 50 TB a month serves >100 per week. architecture designed support bulk searching downloading through Web-accessible application...
Aliment Pharmacol Ther 2011; 34: 51–58 Summary Background Infliximab (IFX) elicits acute severe infusion reactions in about 5% of patients with inflammatory bowel disease (IBD). Aim To investigate the role anti-IFX antibodies (Ab) and other risk factors. Methods The study included all IBD treated IFX at a Danish university hospital until 2010 either continuously (IFX every 4–12 weeks) or episodically (reinitiation after >12 weeks). Anti-IFX Ab were measured using radioimmunoassay. Results...